EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

International Journal of Lung Cancer

ISSN 3117-504X · Elsevier BV

Neueste Artikel

  1. Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study

    Tomoki Tamura, Kazuya Nishii, Yukari Tsubata, Naoki Watanabe, Masahiro Kodani, Takeshi Masuda, Masaaki Inoue, Masahiro Yamasaki, Nobuaki Ochi, Tetsuya Kubota, Hirohisa Ichikawa, Nobuhisa Ishikawa, Shingo Harita, Nobukazu Fujimoto, Ichiro Takata, Soichi Kitaguchi, Tatsuya Nishi, Naoki Nakamura, Katsuyuki Hotta, Katsuyuki Kiura

    Erschienen: 2026-12DOI: 10.1016/j.ijlcan.2026.100065

  2. The changing landscape of stage IV lung squamous cell carcinoma: Long-term trends with immune checkpoint inhibitors and contemporary regimens

    Aastha Dhakal, Emily C. Zabor, Naveen Rehman, Bridget Adcock, Muaz Alsabbagh Alchirazi, Moath Albliwi, Ali Mushtaq, Hadil Zureigat, Monica Lee, Ahmed Nabil Mohamed Hassan, Heya Batah, Preeyal Patel, Meera Patel, Sara Haddad, Yang Wang, Michael Menefee, Khaled Aref Hassan, Marc A. Shapiro, James Stevenson, Alex A. Adjei, Lukas Delasos, Moaath Khader Mustafa Ali

    Erschienen: 2026-12DOI: 10.1016/j.ijlcan.2026.100070

  3. Incidence of leptomeningeal metastasis and prognosis after its development in patients with advanced non-small cell lung cancer: a prospective real-world observational study (CS-Lung-003-linked study 37)

    Nobuhiro Kanaji, Kazuya Nishii, Shoichi Kuyama, Tomoki Tamura, Takeshi Masuda, Shinjiro Sakamoto, Kakuhiro Yamaguchi, Yukari Tsubata, Yoshitaka Iwamoto, Atsuko Hirabae, Ryota Sunami, Masahiro Kodani, Masaaki Yanai, Nagio Takigawa, Nobuaki Ochi, Nobuhisa Ishikawa, Katsuyuki Hotta

    Erschienen: 2026DOI: 10.1016/j.ijlcan.2026.100031

  4. Real-world clinical outcomes of immune checkpoint inhibitors beyond 2 Years in patients with non-small cell lung cancer: A multicenter retrospective study

    Tomoyuki Ogata, Hiroaki Satoh, Masaharu Inagaki, Kunihiko Miyazaki, Toshihiro Shiozawa, Takeshi Numata, Koichi Kurishima, Jun Kanazawa, Yoko Wakai, Tomohiro Tamura, Norihiro Kikuchi, Shigen Hayashi, Norihito Hida, Takanori Ohata, Yasunori Funayama, Shinichiro Tomioka, Hiroko Watanabe, Koji Kanemoto, Kento Yamazaki, Susumu Takahashi, Kentaro Nakamura, Tomohiro Moriya, Takaaki Yamashita, Nobuyuki Hizawa

    Erschienen: 2026DOI: 10.1016/j.ijlcan.2026.100046

  5. Real-world comparison of carboplatin–pemetrexed–bevacizumab versus chemo-immunotherapy in EGFR-mutated lung cancer

    Tadashi Nishimura, Hajime Fujimoto, Hitoshi Sumitani, Yoshihiko Taniguchi, Akihiro Tamiya, Yoshinobu Matsuda, Takumi Fujiwara, Tadashi Sakaguchi, Kentaro Ito, Ayaka Ohiwa, Atsushi Fujiwara, Yukihiro Nakamura, Mayu Kawakami, Soichi Iwanaka, Tomohito Okano, Hisamichi Yuda, Masamichi Yoshida, Osamu Hataji, Masahiro Naito, Naoyuki Nogami, Esteban C. Gabazza, Tetsu Kobayashi

    Erschienen: 2026DOI: 10.1016/j.ijlcan.2026.100049

Jahrgänge

2026 · 45

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.